VTYX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PARDAVIMAS 112554 min ago

@ $2.33

Išleistas: 14 vas. 2024 @ 16:30

Grąža: 109.44%

Ankstesnis signalas: vas. 12 - 21:19

Ankstesnis signalas: Pirkimas

Grąža: -6.99 %

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 21:24):

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders...

Stats
Šios dienos apimtis	816 882
Vidutinė apimtis	4.06M
Rinkos kapitalizacija	344.04M
EPS	$0 ( 2024-03-28 )
Kita pelno data	( $-0.670 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.480
ATR14	$0.0110 (0.23%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-12	Subramaniam Somu	Sell	695 339	Common Stock
2024-04-12	Nsv Partners Iii Lp	Sell	695 339	Common Stock
2024-04-02	Krueger Christopher W	Sell	1 651	Common Stock
2024-04-02	Nuss John	Sell	1 651	Common Stock
2024-04-02	Mohan Raju	Sell	4 312	Common Stock

INSIDER POWER
-9.40
Last 100 transactions
Buy: 2 083 814 \| Sell: 2 354 020

Tūris Koreliacija

Ilgas: 0.03 (neutral)

Trumpas: -1.00 (very strong negative)

Signal:(48.687) Neutral

Ventyx Biosciences, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
SVRA	0.94
SY	0.936
IDCC	0.93
OVID	0.929
NVCN	0.929
HURC	0.926
OVLY	0.919
GPACU	0.919
VBOC	0.918
BYNOU	0.916

10 Labiausiai neigiamai susiję koreliacijos
NAKD	-0.93
PRPH	-0.91
ORPH	-0.903
CHKEL	-0.902
CSSEP	-0.902
PROC	-0.9
ALXO	-0.898
HCAQ	-0.897
TRIT	-0.895
AHPI	-0.892

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Ventyx Biosciences, Inc. Koreliacija - Valiuta/Žaliavos

-0.67
( moderate negative )

-0.57
( weak negative )

0.00
( neutral )

-0.37
( neutral )

-0.77
( moderate negative )

0.49
( neutral )

Ventyx Biosciences, Inc. Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-941 000 (0.00 %)
EPS:	$-3.30

FY	2023
Pajamos:	$0
Bruto pelnas:	$-941 000 (0.00 %)
EPS:	$-3.30

FY	2022
Pajamos:	$0
Bruto pelnas:	$-470 000 (0.00 %)
EPS:	$-2.06

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-6.65

Financial Reports:

No articles found.

Ventyx Biosciences, Inc.

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.